The U.S. Food and Drug Administration today (March 25) approved the drug Yervoy (ipilimumab) to treat patients with late-stage, metastatic melanoma, the most dangerous type of skin cancer.
Yervoy works by blocking a molecule known as cytotoxic T-lymphocyte antigen, or CTLA-4, which hinders the body’s immune system in fighting off cancerous cells. Yervoy allows the immune system to recognize, target, and attack cells in melanoma tumors, according to an FDA report.
“Late-stage melanoma is devastating, with very few treatment options for patients, none of which previously prolonged a patient’s life,” Dr. Richard Pazdur, director of the Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. “Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live longer by taking this treatment.”
Melanoma is the leading cause of death from skin disease . An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and about 8,700 people died from the disease, according to the National Cancer Institute.
The safety and effectiveness of Yervoy, which is administered intravenously, were established in a single international study of 676 patients with melanoma. All patients in the study had stopped responding to other FDA-approved or commonly used treatments for melanoma , and their disease had spread or could not be surgically removed.
Patients received Yervoy plus an experimental tumor vaccine called gp100, Yervoy alone, or the vaccine alone. Those who received Yervoy plus the vaccine or Yervoy alone lived an average of about 10 months, while those who received only the experimental vaccine lived an average of 6.5 months.
Common side effects from using Yervoy include fatigue, diarrhea, skin rash, endocrine deficiencies (gland or hormone), and inflammation of the intestines (colitis). Severe to fatal autoimmune reactions were seen in 12.9 percent of patients treated with Yervoy.
When severe side effects occurred, Yervoy was stopped and corticosteroid treatment was started. Not all patients responded to this treatment . Patients who did respond in some cases did not see any improvement for several weeks.
Due to the unusual and severe side effects associated with Yervoy, the therapy is being approved with a Risk Evaluation and Mitigation Strategy to inform health care professionals about these serious risks. A medication guide will also be provided to patients to inform them about the therapy’s potential side effects.
Yervoy is marketed by New York City-based Bristol-Myers Squibb.
Pass it on: The FDA has approved Yervoy to treat late-stage melanoma, the most severe kind of skin cancer.
- Melanoma: Symptoms, Treatment and Prevention
- Young, Wealthy Women Lead Surge in Melanoma
- 10 Dos and Donâts to Reduce Your Risk of Cancer
Follow MyHealthNewsDaily on Twitter @MyHealth_MHND.